

Journal Pre-proof



Functional solubilisation of the β_2 -adrenoceptor (β_2 AR) using Diisobutylene maleic acid (DIBMA)

C.R. Harwood, D.A. Sykes, B. Hoare, F.M. Heydenreich, R. Uddin, D.R. Poyner, S.J. Briddon, D.B. Veprintsev

PII: S2589-0042(21)01333-X

DOI: <https://doi.org/10.1016/j.isci.2021.103362>

Reference: ISCI 103362

To appear in: *ISCIENCE*

Received Date: 21 July 2020


Revised Date: 16 July 2021

Accepted Date: 25 October 2021

Please cite this article as: Harwood, C.R., Sykes, D.A., Hoare, B., Heydenreich, F.M., Uddin, R., Poyner, D.R., Briddon, S.J., Veprintsev, D.B., Functional solubilisation of the β_2 -adrenoceptor (β_2 AR) using Diisobutylene maleic acid (DIBMA), *ISCIENCE* (2021), doi: <https://doi.org/10.1016/j.isci.2021.103362>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021



Functional solubilisation of the β_2 -adrenoceptor (β_2 AR) using Diisobutylene maleic acid (DIBMA)

C. R. Harwood^{1,2}, D. A. Sykes^{1,2}, B. Hoare^{1,2}, F. M. Heydenreich^{3,#}, R. Uddin^{1,4}, D. R. Poyner^{1,4}, S. J. Briddon^{1,2,*}, D. B. Veprintsev^{1,2,*,&}

¹Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands NG7 2UH, UK

²Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK

³Laboratory of Biomolecular Research, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland and Department of Biology, ETH Zürich, 8093 Zürich, Switzerland

⁴School of Life and Health Sciences, Aston University, Birmingham B47ET, U.K

#Current address: Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA

*Corresponding authors dmitry.veprintsev@nottingham.ac.uk and stephen.bridon@nottingham.ac.uk

&Lead contact

Abstract

The β_2 -adrenoceptor (β_2 AR) is a well-established target in asthma and a prototypical GPCR for biophysical studies. Solubilisation of membrane proteins has classically involved the use of detergents. However, the detergent environment differs from the native membrane environment and often destabilises membrane proteins. Use of amphiphilic copolymers is a promising strategy to solubilise membrane proteins within their native lipid environment in the complete absence of detergents. Here we show the isolation of the β_2 AR in the polymer Diisobutylene maleic acid (DIBMA). We demonstrate that β_2 AR remains functional in the DIBMA lipid particle (DIBMALP) and shows improved thermal stability compared to the n-Dodecyl- β -D-Maltopyranoside (DDM) detergent solubilised β_2 AR. This unique method of extracting β_2 AR offers significant advantages over previous methods routinely employed such as the introduction of thermostabilising mutations and the use of detergents, particularly for functional biophysical studies.

Introduction

G protein coupled receptors (GPCRs) are the largest family of membrane proteins within the human genome and are responsible for modulating a broad range of hormonal, neurological and immune responses. It is well established that GPCRs have a large therapeutic potential. Indeed, GPCRs currently represent 34% of all US food and drug administration (FDA) approved drugs, with 475 drugs targeting over 100 diverse receptors (Hauser, Attwood et al. 2017). The β_2 -adrenoceptor (β_2 AR) is a rhodopsin-like family GPCR (Schioth and Fredriksson 2005) and member of the adrenoceptor family, which signals primarily through coupling the heterotrimeric G_s protein. It is a well-established target for asthma and has become one of the most studied GPCRs with several structural (Wacker, Fenalti et al. 2010, Rasmussen, DeVree et al. 2011, Bang and Choi 2015) and detailed biophysical studies (Manglik, Kim et al. 2015, Gregorio, Masureel et al. 2017) into its activation mechanism.

A prerequisite for completion of biophysical and structural studies is the extraction and isolation of the β_2 AR from its cellular environment. Classically, this has involved the use of detergents, in the case of the β_2 AR and other GPCRs, *n*-dodecyl- β -D-maltopyranoside (DDM) is most often used (Munk, Mutt et al. 2019). However, it is well established that detergent micelles do not recapitulate the environment of the cell membrane and, as such, protein stability is compromised. Moreover, there is strong evidence that phospholipid composition affects β_2 AR function (Dawaliby, Trubbia et al. 2016). Cholesterol in particular appears associated with the β_2 AR in crystal structures (Cherezov, Rosenbaum et al. 2007), and improves β_2 AR stability (Zocher, Zhang et al. 2012) and function (Paila, Jindal et al. 2011). Multiple studies (Leitz, Bayburt et al. 2006, Whorton, Bokoch et al. 2007) have mimicked the native membrane environment and improved protein stability through reconstitution of membrane proteins in liposomes, amphipols or synthetic nanodiscs, however these all require initial use of detergents to extract the membrane protein from the membrane.

Recently, it was discovered that styrene maleic acid (SMA) copolymer directly incorporates into biological membranes and self-assembles into native nanoparticles, known as Styrene Maleic Acid Lipid Particles (SMALPs) (Knowles, Finka et al. 2009) (Stroud, Hall et al. 2018), avoiding the use of detergents at all stages. This has provided a novel method for the solubilisation of membrane proteins with their native receptor associated phospholipids, although some preferential extraction of native lipids occurs (Barniol-Xicota and Verhelst 2021).

SMA has been used to solubilise a range of membrane proteins (Dorr, Koorengevel et al. 2014, Gulati, Jamshad et al. 2014, Sun, Benlekbir et al. 2018) including GPCRs (Jamshad, Charlton et al. 2015, Bada Juarez, Munoz-Garcia et al. 2020) for both structural and biophysical studies. Such studies either improved protein stability compared to detergent or have allowed extraction of membrane proteins that were previously unstable in detergents. There is, however, evidence that the conformational flexibility of GPCRs within SMALPs is restricted (Mosslehy, Voskoboinikova et al. 2019, Routledge, Jamshad et al. 2020) therefore differing from the native state of the protein. Furthermore, the high absorbance of SMA copolymer in the far-UV region makes optical spectroscopic studies of membrane proteins that are encapsulated within SMALPs challenging (Gulamhussein, Meah et al. 2019).

An alternative to SMA is Diisobutylene maleic acid (DIBMA), a copolymer which was developed specifically for the extraction of membrane proteins from the intact bilayer (Oluwole, Danielczak et al. 2017). Compared to SMALPs, DIBMALPs are believed to have only a mild effect on lipid packing, be compatible with optical spectroscopy in the far UV range, and tolerate low millimolar concentrations of divalent cations (Oluwole, Danielczak et al. 2017). This makes DIBMALPs far more amenable for functional biophysical studies. DIBMALPs have been shown to contain lipids of the cell membranes using lipidomic approaches (Barniol-Xicotá and Verhelst 2021). Despite the natural polydispersity in length of polymer molecules, DIBMALPs form a monodisperse in size population (Oluwole, Danielczak et al. 2017, Gulamhussein, Meah et al. 2019, Gulamhussein, Uddin et al. 2020). Inclusion of integral membrane proteins such as OmpLA and α -synuclein did not affect their size distribution (Oluwole, Danielczak et al. 2017, Adão, Cruz et al. 2020).

In this study we demonstrate isolation of the functional β_2 AR from the mammalian cell membrane using DIBMA, with improved thermal stability compared to conventional detergent-based methods.

Results

Extraction of the β_2 AR from membranes using DIBMA.

The β_2 AR was extracted from the membrane of mammalian (T-RexTM-293) cells using either 1% DDM, or 3% DIBMA (Figure 1A). Figure 1B shows a comparison of the solubilisation efficiency of 1% DDM and 3% DIBMA as $90\pm 11\%$ and $32\pm 7\%$ respectively. Figure 1C shows fluorescence size exclusion chromatography (FSEC) of these β_2 AR. Figure 1C shows a peak at 1.6-1.8mL, roughly 75kDa which corresponds to DDM- β_2 AR or DIBMALP- β_2 AR. Additionally, there was a higher molecular weight peak for the DIBMALP- β_2 AR and two higher molecular weight peaks for DDM- β_2 AR. These peaks are presumed to correspond to protein aggregates. Peaks were confirmed by in gel fluorescence (figure SF2A-B).

DIBMALP- β_2 AR retains its pharmacology

A time-resolved fluorescence resonance energy transfer (TR-FRET) based ligand binding assay was established to investigate if the β_2 AR remained functional when extracted from the HEK cell membranes into DIBMALPs. Förster resonance energy transfer (FRET) is the non-radiative transfer of energy from an excited donor fluorophore to a ground state acceptor fluorophore. Energy transfer will only occur when the fluorescent emission spectrum of the donor overlaps with the excitation spectrum of the acceptor fluorophore, and these fluorophores are within ~ 10 nm of each other. In this study the SNAP tag on the N terminus of the β_2 AR was labelled with donor fluorophore terbium cryptate (Lumi4-Tb). Excitation of terbium cryptate using a laser allowed proximity of the β_2 AR to acceptor fluorophores fluorescent propranolol and the BIODIPY F-L cysteine dye to be quantified for ligand binding and thermostability assays respectively. The specific labelling of the SNAP tag meant that it was not necessary to purify the β_2 AR in these studies. TR-FRET is becoming an increasingly used technique for ligand binding studies (Emami-Nemini, Roux et al. 2013).

Figure 2 shows saturation binding experiments for the fluorescent antagonist S-propranolol-red-630/650 (F-propranolol) binding membrane- β_2 AR, DDM- β_2 AR and DIBMALP- β_2 AR. The β_2 AR retained ligand binding ability when extracted from the

membrane using both DDM and using the copolymer DIBMA. These data showed comparable affinities for F-propranolol binding to the β_2 AR in membranes ($pK_d = 7.50 \pm 0.05$), DDM ($pK_d = 7.10 \pm 0.08$) and DIBMA ($pK_d = 7.00 \pm 0.13$), although with slightly reduced affinity in DIBMA compared to membranes ($P=0.02$, one-way ANOVA and Tukey's multiple comparison).

In order to better understand if the conformational state of the receptor or its ability to adopt different states in DIBMALPs was affected we investigated its pharmacology using the full agonist isoprenaline, the antagonist propranolol and the inverse agonist ICI 118,551 in equilibrium competition binding assays using F-propranolol as the tracer (Figure 3). Increasing concentrations of each competing ligand produced a reduction in the specific binding of F-propranolol to the β_2 AR in membranes, DDM and DIBMALPs with largely comparable pK_i values (Table 1). The only statistically significant difference was between isoprenaline binding to the β_2 AR found in membranes versus the DDM solubilised β_2 AR ($p=0.03$) (one-way ANOVA and Tukey's post hoc). The slopes of all curves were similar to 1.

DIBMALP- β_2 AR shows improved stability

Next, we investigated the thermostability of the DIBMALP- β_2 AR using a novel ThermoFRET assay (Figure 4, Table 2). Labelling of the SNAP tag on the N terminus of the receptor with Lumi4-Tb allowed thermostability to be investigated without purifying the receptor. β_2 AR unfolding was initially measured by quantifying TR-FRET between Lumi4-Tb and BODIPY™ FL L-Cystine that covalently reacts with cysteines which become exposed as the receptor unfolded (Tippett, Hoare et al. 2020).

Figure 4B shows the T_m of DDM solubilised β_2 AR as $35.2 \pm 2.4^\circ\text{C}$. Ligand-induced shifts in thermostability were seen when the DDM solubilised β_2 AR was incubated with F-propranolol ($T_m = 37.8 \pm 0.4^\circ\text{C}$, $p > 0.05$) and cyanopindolol ($T_m = 41.9 \pm 0.1^\circ\text{C}$, $p = 0.04$) (one-way ANOVA and Tukey's multiple comparison test). Figure 4A shows the T_m of β_2 AR in the membrane environment as $62.42 \pm 0.2^\circ\text{C}$. No ligand induced shift was observed when β_2 AR membranes were pre-incubated with F-propranolol or cyanopindolol, this suggests the unfolding of the receptor itself is not directly measurable and perhaps that these data show the disintegration of the membrane itself. Figure 4C shows TR-FRET thermostability data for the DIBMALP- β_2 AR, this data did not fit a Boltzmann sigmoidal curve as the top end of the temperature range did not plateau. No effect on any part of the curve was observed with the addition of F-propranolol or cyanopindolol. Therefore, as was the case in membranes, the observed thermostability changes in DIBMALPs likely reflect the melting of the lipid particles as opposed to the receptor itself.

We then investigated the thermostability of the β_2 AR by measuring the reduction in TR-FRET binding of F-propranolol over an increasing temperature range (Figure 4D). The resulting data suggests similar T_m values determined for the membrane- β_2 AR ($60.1 \pm 0.6^\circ\text{C}$) and DDM- β_2 AR ($36.0 \pm 0.6^\circ\text{C}$) to those obtained using BODIPY™ FL L-Cystine in the presence of F-propranolol. Unpaired two-tailed t tests showed no statistically significant differences between membrane- β_2 AR +F-propranolol or DDM- β_2 AR+F-propranolol T_m values obtained using ThermoFRET Vs that obtained by measuring the decrease in F-propranolol ligands binding.

Thermostability of DIBMALP- β_2 AR measured by the decrease in F-propranolol binding gave a curve that could be fitted to a Boltzmann with a T_m value of 46.8 ± 2.1 °C. This T_m value is statistically significant from that of membrane- β_2 AR ($p=0.0002$) and DDM- β_2 AR ($p=0.0009$) obtained by the same method (one-way ANOVA and Tukey's multiple comparison test). Therefore, the DIBMALP- β_2 AR shows approximately 10°C improved stability over the conventional DDM- β_2 AR. We also observed differences in the slopes of DIBMALP- β_2 AR and DDM- β_2 AR thermostability curves obtained by this method, these were -3.2 and -2.7 respectively. Additionally, we investigated the thermostability of another rhodopsin-like GPCR, the adenosine 2A receptor (A_{2A} AR) when solubilised into a DIBMALP using fluorescent adenosine receptor antagonist (F-XAC) (Hello Bio, UK). Measuring the reduction in F-XAC bound to A_{2A} AR over an increased temperature range gave a T_m value of $44.8^\circ\text{C} \pm 0.7$, which was not statistically significantly different from that of the DIBMALP- β_2 AR.

Discussion

The β_2 AR has become the prototypical GPCR for understanding GPCR structure and the molecular basis of signaling (Bang and Choi 2015) (Gregorio, Masureel et al. 2017), these studies have all required the use of detergents to extract the β_2 AR from the plasma membrane. Detergents do not recapitulate the complexity of the native membrane environment and are known to damage membrane proteins. Here, we demonstrate that the polymer DIBMA can be used to extract the β_2 AR from the plasma membrane, together with its native phospholipids, avoiding the use of detergents at any stage.

Similarly, to (Gulamhussein, Uddin et al. 2020) we show that DIBMA can be used to extract GPCRs from cell membranes and that the solubilisation efficiency of DIBMA is lower than that of SMA or in our case the detergent DDM. We then used TR-FRET ligand binding studies to show that the β_2 AR remained functional inside the DIBMALP (Figure 2-3). Ligand binding data showed comparable affinity (pK_d/K_i) values for the β_2 AR binding F-propranolol, propranolol, ICI 118,551 and isoprenaline solubilised in DIBMA compared to membranes. Although the difference in pK_d values for F-propranolol binding membranes- β_2 AR (7.5 ± 0.05) and DIBMALP- β_2 AR (7.0 ± 0.13) was statistically different ($P=0.02$), this is only a 3-fold difference and the pharmacological importance of this remains to be seen. There was no statistical difference between F-propranolol pK_d values for DDM- β_2 AR and DIBMALP- β_2 AR. All ligand binding curves showed one phase binding and a slope of 1 indicating no cooperativity of ligand binding.

While the pK_d values for different preparations of the receptor were comparable, the signal amplitude obtained for F-propranolol binding DIBMALP- β_2 AR in TR-FRET experiments was 3-fold lower than for membranes- β_2 AR. This reduction in signal amplitude could be due to an effect of the DIBMA polymer on the TR-FRET, for example fluorescence quenching. Alternatively, it could reflect that a lower fraction of the ligand binding capable β_2 AR receptors are present compared to the amount of Tb3+ labelled receptor molecules. However, it should be noted that the assay window for DDM- β_2 AR was higher than that of membranes whilst it would be expected that less β_2 AR is functional, suggesting that the solubilization environment can influence the observed signal amplitude. Whilst the concentration of β_2 AR used in each experimental condition was quantified using 620nm emission of Lumi4-Tb, it was not

possible to account for difference in Lumi4-Tb quantum yield in the membrane, DDM and DIBMALP environments.

It has been shown that the conformational changes of another class A GPCR, Rhodopsin II in response to activation by light are restricted in SMALPs (Mosslehy, Voskoboynikova et al. 2019). We chose to study the binding of a full agonist (isoprenaline), antagonist (propranolol) and inverse agonist (ICI 118,551) to be able to ascertain if conformational states of the β_2 AR differed in a membrane, DDM micelle, or DIBMALP environment. A substantial increase or decrease in pK_i value would demonstrate an increase or decrease in the population of the receptors in the conformational state stabilized by the ligand, and therefore a difference in the conformational landscape of the receptor. As there was no statistically significant difference in pK_i values between membrane- β_2 AR and DIBMALP- β_2 AR it can be concluded that the DIBMALP- β_2 AR represents the native conformational landscape of the β_2 AR. The difference in pK_i value between DDM- β_2 AR (6.3 ± 0.13) and membrane- β_2 AR (5.5 ± 0.2) for isoprenaline was statistically significant ($p=0.03$), this may indicate a change in the conformational state of β_2 AR in the DDM micelle compared to its native conformational state. Propranolol, ICI 118,551 and isoprenaline pK_i values obtained in this study are in line with the previous studies that investigate the affinity of these compounds for the β_2 AR (Baker 2005) (Sykes, Parry et al. 2014).

Furthermore, we employed a ThermoFRET based thermostability assay to investigate the stability of the DIBMALP- β_2 AR compared to the DDM- β_2 AR. We show the thermostability of DIBMALP- β_2 AR is 10°C higher than that of the DDM- β_2 AR. It was not possible to find any thermostability data for the β_2 AR in synthetic nanodiscs; however, the only other method to show a similar (11°C) increase in thermostability for β_2 AR is that of thermostabilising mutations (Serrano-Vega and Tate 2009). Since these mutations also lead to a shift in the β_2 AR's conformational landscape to the antagonist-bound and inactive form, the DIBMALP- β_2 AR offers a clear advantage for study of receptor function.

Moreover, thermostability data for DIBMALP- β_2 AR using F-propranolol showed a T_m value that was very similar to the T_m of DIBMALP-A_{2A}AR. In addition, no shift in thermostability was observed for DIBMALP- β_2 AR preincubated with F-propranolol or the high-affinity antagonist cyanopindolol. It therefore seems likely that this T_m value of $\sim 45^\circ\text{C}$ for DIBMALP- β_2 AR corresponds to the melting temperature of the DIBMALP. Interestingly, this T_m value of $\sim 45^\circ\text{C}$ is lower than that of $\sim 50^\circ\text{C}$ reported for SMALP-A_{2A}AR extracted from yeast membranes using a radioligand based thermostability assay but slightly higher than $\sim 42^\circ\text{C}$ A_{2A}AR extracted from mammalian (HEK293) membranes (Jamshad, Charlton et al. 2015). The T_m of $60.2 \pm 0.2^\circ\text{C}$ seen for β_2 AR in membranes was also unaffected by the presence of F-propranolol and cyanopindolol. As this T_m of $60.2 \pm 0.2^\circ\text{C}$ is statistically significant from that of the DIBMALPs it seems likely that the T_m of $\sim 45^\circ\text{C}$ corresponds to disruption of the protein-lipid-polymer particles, whilst the T_m of $60.2 \pm 0.2^\circ\text{C}$ corresponds to the melting or disruption of the membrane itself. We also noted a shallower slope for DIBMALP- β_2 AR (-3.2) compared to DDM- β_2 AR (-2.7), this broader transition may reflect the more heterogenous nature of DIBMALPs compared to the detergent micelle.

In summary, here we show the utility of the copolymer DIBMA to solubilise the β_2 AR in a functional form. We show that this method offers improved stability over the

use of the conventional detergent DDM and has allowed us to maintain the native environment and ligand binding activity of the β_2 AR. This could therefore provide an improved solubilisation method for structural and biophysical studies. Moreover, we demonstrate this using novel TR-FRET ligand binding based methods that should allow for easier screening of membrane protein solubilisation conditions and anticipate that this approach could be applied to other GPCRs.

Limitations of the study

As discussed above, one limitation of the study is that we cannot be certain about the cause of the decreased signal window in the ligand binding assays for DIBMALP- β_2 AR Vs membrane- β_2 AR and DDM- β_2 AR. This could be indicative of less DIBMALP- β_2 AR being functional compared to in membranes, although there could be a number of other reasons such as decrease quantum yield of either donor or acceptor, as discussed. Furthermore, although we showed that DIBMALP- β_2 AR retains ligand binding, we have not tested other functionality of the receptor such as its ability to activate G proteins or recruit arrestins . Such studies would require the purification of G proteins which was beyond the scope of this study.

STAR Methods**Resource availability****Lead contact**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Dmitry Veprintsev (Dmitry.Veprintsev@nottingham.ac.uk).

Materials availability

Plasmids generated in this study are available from the lead contact upon request, subject to the MTA with the University of Nottingham.

Data and code availability

Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

Experimental model and subject details

No human subject or animal models were used in this study. The cell lines T-RexTM-293 cells stably expressing pcDNA4TO-TS-SNAP- β_2 AR or pcDNA4TO-TS-SNAP-A_{2A} were used in this study. These cell lines were maintained in high glucose DMEM (Sigma D6429) with 10% foetal bovine serum (FBS), 5 μ g/ μ L blasticidin and 20 μ g/ μ L zeocin, at 37°C and 5% CO₂.

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Bacterial and virus strains		
One Shot TM TOP10 chemically competent E.coli	Invitrogen	C404010
Chemicals, peptides, and recombinant proteins		
SNAP-Lumi4-Tb	Cis bio	SSNPTBX
n-Dodecyl- β -D-maltopyranoside (DDM)	Anatrace, OH, US	D3010S
Diisobutylene Maleic acid (DIBMA)	Anatrace, OH, US	BMA1011
5% Magstrep 'type3' XT magnetic bead suspension	IBA Lifesciences, DE	2-4090-002
633/650 S-propranolol-red	CellAura, UK, supplied by Hello Bio, UK	Cat no. HB7817
Fluorescent XAC CA200634	CellAura, UK, supplied by Hello Bio, UK	Cat no. HB7814
ICI, 118 551 hydrochloride	Selleckchem, US	Cat no. S8114 1217094-53-5
Isoprenaline hydrochloride	Sigma	Cat no. I5627 CAS-51-30-9
(s)-(-)-Propranolol hydrochloride	Tocris, UK	Cat no. 0834 CAS 4199-10-4
Cyanopindolol hemifumerate	Tocris, UK	Cat no. 0993 CAS 69906-86-1

BODIPY™ FL L- Cystine dye	Molecular Probes, US	B20340
NuPAGE™ MOPS SDS running buffer (x20)	Invitrogen	NP0001
Experimental models: Cell lines		
T-Rex™-293 cells (parent cell line)	Invitrogen	Cat.no. R71007
Stable cell line T-Rex™-293 expressing TS-SNAP- β 2AR	plasmid generated in this study	This study
Stable cell line T-Rex™-293 expressing TS-SNAP- A _{2A}	plasmid generated in this study	This study
Oligonucleotides		
CMV forward sequencing primer	Genewiz, UK	CGCAAATGGG CGGTAGGCGT G
BGH reverse sequencing primer	Genewiz, UK	TAGAAGGCACA GTCTGAGG
Recombinant DNA		
TS-SNAP- β 2AR in pcDNA4/TO	This study	This study, SI
TS-SNAP- A _{2A} in pcDNA4/TO	This study	This study, SI
Software and algorithms		
GraphPad Prism 8.0.0	GraphPad software, CA, US	www.graphpad.com
PHERASTAR v5.41.	BMG, UK	BMG Pherastar FSX platereader
Other		
Shimadzu Prominence modular HPLC system	Shimadzu, Kyoto, Japan	Prominence modular HPLC system
Yarra 1.8 μ m SEC-x300 2.5mL column	Phenomenex, CA, US	00H-4743-E0-SS
TruPage™ Precast Gels 4-20%.	Sigma	PCG2008
PHERASTAR® FSX equipped with Time Resolved Fluorescence lasers and module, and TR337/665/620 and TR337/520/620modules	BMG, UK	PHERASTAR® FSX
ProxiPlate-384 Plus	PerkinElmer, MA, US	6008280
OptiPlate-384	PerkinElmer, MA, US	6007290
GE Amersham Typhoon™	GE, US	GE Amersham Typhoon™

Method details

Molecular biology

The construct pcDNA4TO-TwinStrep (TS)-SNAP- β_2 AR was generated by amplification of the SNAP and β_2 AR sequences of the pSNAPf-ADRB2 plasmid (NEB) and insertion into pcDNA4TO-TS using Gibson assembly (Heydenreich, Miljus et al. 2017, Heydenreich, Miljuš et al. 2020). The construct pcDNA4TO-TS-SNAP-A_{2A} was generated by amplifying the A_{2A} receptor from the pDNA3.1 SNAP A_{2A} construct described in (Comeo, Kindon et al. 2020) and inserting into pcDNA4TO-TS-SNAP vector using Gibson assembly. This therefore gave the construct pcDNA4TO-TS-SNAP-A_{2A}. Both constructs used a signal peptide based on the 5HT_{3A} receptor to increase protein folding and expression.

Transfection and mammalian cell culture

pcDNA4TO-TS-SNAP- β_2 AR or pcDNA4TO-TS-SNAP-A_{2A} were stably transfected into T-RexTM-293 cells (Invitrogen) using polyethylenimine (PEI). A mixed population stable line was selected by resistance to 5 μ g/mL blasticidin and 20 μ g/mL Zeocin. Stable cell lines were maintained in high glucose DMEM (Sigma D6429) with 10% foetal bovine serum (FBS), 5 μ g/ μ L blasticidin and 20 μ g/ μ L zeocin, at 37°C and 5% CO₂. When ~70% confluent TS-SNAP- β_2 AR expression was induced with 1 μ g/mL tetracycline. Cells were left to express for 50hrs before harvesting.

Labelling TS-SNAP- β_2 AR with Terbium cryptate or SNAP-AlexaFluor488 or 647

Media was aspirated from T175 flasks and adherent cells washed twice at room temperature with Phosphate Buffered Saline (PBS). Adherent cells were labelled with 100nM SNAP-Lumi4-Tb labelling reagent in Labmed buffer (both Cisbio, UK) for 1 hr at 37°C and 5% CO₂, or for 30mins with SNAP-AlexaFluor 488 (NEB) in cell culture media. Cells were washed twice more with PBS and detached with 5mL non enzymatic cell dissociation solution (Sigma, UK). Cells were pelleted by centrifugation for 10 min at 1000xg, supernatant was removed, and cell pellets frozen at -80°C.

TS-SNAP- β_2 AR membrane preparation

Cell pellets were thawed on ice and resuspended in 20mL buffer B (10mM HEPES and 10mM EDTA, pH 7.4). Suspensions were homogenised using 6 x 1 sec pulses of a Polytron tissue homogeniser (Werke, Ultra-Turrax). Suspensions were centrifuged at 48,000xg and 4°C for 30 min, supernatant was removed and resuspended and centrifuged again as above. Resulting pellets were resuspended in buffer C (10mM HEPES and 0.1mM EDTA, pH 7.4) and frozen at -80°C.

Solubilisation of TS-SNAP- β_2 AR using DDM or DIBMA

Membranes were incubated with 3% DIBMA (w/v) (Anatrace, UK) in 20mM HEPES, 10% (v/v) glycerol, and 150mM NaCl, pH 8 at room temperature or 1% DDM (w/v), 20mM HEPES, 5% (v/v) glycerol, and 150mM NaCl, pH 8 at 4°C for 2-3 h. Samples were clarified by ultracentrifugation at 4°C for 1hr at 100,000xg for ligand binding assays and 16900xg at 4°C for 45min for thermostability assays.

Affinity purification of DDM or DIBMALP TS-SNAP- β_2 AR

Solubilised DDM-TS-SNAP- β_2 AR and DIBMALP- β_2 AR samples were purified using 20 μ L of 5% MagStrep "type3" XT magnetic beads suspension (IBA). Beads were prepared by removal of supernatant using magnetic rack and 2x washes in 200 μ L

solubilisation buffers before resuspension in samples. Samples were incubated with beads for 2hrs at 80RPM on a roller in cold room. Supernatant was then removed from beads using magnetic rack and beads were washed twice with wash buffer (20mM HEPES, 10% glycerol, 150mM NaCl, pH 7.5 with 0.1% DDM for DDM sample only), before resuspension in 50 μ L elution buffer. Elution buffer consisted of 1part 10X buffer BXT (IBA) and 9 parts wash buffer. Elution took place for 2 hours at 80RPM on a roller in cold room. Sample were then separated from beads using magnetic rack.

Fluorescence size exclusion chromatography (FSEC)

30 μ L crude lysate samples of Alexa488-DDM or DIBMALP- β 2AR were run of Yarra 1.8 μ m SEC-x300 2.5mL column (Phenomenex, CA, US) using shimadzu prominence HPLC system. Running buffer consisted of 20mM HEPES, 150mM NaCl, 5% glycerol, and 0.03% DDM for DDM- β 2AR sample only. FSEC took place at a flow rate of 0.2mL/min and 0.2mL fractions collected. Samples were excited at 488nm, and emission collected at 520nm. GE HMW calibration kit was use as the standard.

In gel fluorescence

15 μ L of each FSEC fraction was run on TruPage™ 4-20% Bis-Tris 17 well gel using NuPage™ LDS sample loading buffer with 5mM Dithiothreitol (DTT) and NuPage™ MOPs running buffer. Gels were run for 50min at 200V. Samples were not boiled prior to gel electrophoresis. 5 μ L PageRuler™ Prestained Protein Ladder (10-140kDa). was used as the ladder. Gels were scanned on GE Typhoon scanner using Fluorstage and Cy2 or Cy5 filter sets. PMT was set to auto and pixel size to 200 μ m.

TR-FRET ligand binding assays

TR-FRET between the donor Lumi4-Tb and the fluorescent acceptors 633/650 S-propranolol-red (CellAura, UK, supplied by Hello Bio, UK, cat no. HB7817) (F-propranolol) was measured by exciting at 337nm and quantifying emission at 665nm and 620nm using a PheraStar FSX (BMG Labtech) and HTRF 337 665/620 module (BMG Labtech). Assay buffer consisted of 20mM HEPES, 5% glycerol, 150mM NaCl, and 0.5% Bovine Serum Albumin (BSA), pH 8.0 for DDM solubilised samples 0.1% DDM was used. All binding assays used a final concentration of 1% Dimethyl sulfoxide (DMSO), assay volume of 30 μ L, 384 well OptiPlates (PerkinElmer, US) and 3 μ M cyanopindolol was used to determine non-specific binding (NSB). Receptors were added to plates last, and the plates were incubated at room temperature for 45 mins prior to reading. For competition binding assays 100nM of F-propranolol was used for membrane and DDM samples and 200nM F-propranolol for DIBMA samples.

ThermoFRET thermostability assays

Solubilised Lumi4-Tb labelled β 2AR was incubated with 10 μ M BODIPY™ FL L-Cystine dye (Molecular Probes, U.S) with or without 200nM F-propranolol or 100 μ M cyanopindolol, for 15 mins on ice in 20mM HEPES, 150mM NaCl, 5% glycerol, 0.5% BSA, pH8. For DDM samples 0.1% DDM was used. 20 μ L samples were added to each well of a 96-well PCR plate and incubated for 30 min over a temperature gradient of 20-78°C across the plate using alpha cycler 2 PCR machine (PCRmax, U.K). Samples were transferred to a 384-well proxiplate (PerkinElmer, U.S). TR-FRET between BODIPY™ FL L-Cystine dye and Lumi4-Tb was read by exciting at 337nm and reading emission at 620nm and 520nm using Pherstar FSX and 337 520/620

module (BMG Labtech). F-propranolol and fluorescent XAC (F-XAC) (CellAura, UK) binding was measured using HTRF 337 665/620 module as above.

Data analysis

TR-FRET ligand binding data

Total and NSB for F-propranolol binding to the β_2 AR was fitted to one-site models in GraphPad Prism 8 according to equations 1 and 2.

$$Total\ binding = \left[\frac{Bmax * X}{(K_d + X)} \right] + [NS * X + background]$$

Equation 1

Where:

NS = slope of linear nonspecific binding

Background = Y when X is 0

Bmax = the maximum specific binding

K_d = the equilibrium dissociation constant

Y = specific binding

X = concentration of tracer

$$NSB = [NS * X + background]$$

Equation 2

Specific binding of F-propranolol to the β_2 AR was fitted to the one site specific binding model in GraphPad Prism 8 according to equation 3. Final K_d values were taken as an average of K_d values from individual specific curve fits.

$$Y = \frac{Bmax * X}{(K_d + X)}$$

Equation 3

Where:

Y = specific binding

K_d = the equilibrium dissociation constant of the labelled ligand

Equilibrium competition binding data was fitted to the One site Fit K_i model in GraphPad Prism 8 according to equation 4 and 5. Final K_i values were taken as an average of individual curve fits.

$$Y = \frac{(Top - Bottom)}{(1 + 10^{(x - LogIC_{50})}) + Bottom}$$

Equation 4

Where:

Y = binding of tracer

IC_{50} = the concentration of competing ligand which displaces 50% of radioligand specific binding.

$$K_i = \frac{IC_{50}}{1 + \left(\frac{[L]}{K_d}\right)}$$

Equation 5

Where:

K_i = the inhibition constant of the unlabelled ligand

$[L]$ = concentration of labelled ligand

K_d = the equilibrium dissociation constant of the labelled ligand.

ThermoFRET thermostability curves

All ThermoFRET thermostability data from each experiment was fitted to a Boltzmann sigmoidal curve using GraphPad Prism 8 according to equation 6 to obtain a melting temperature (T_m) value. Final T_m values were taken as an average of T_m values from individual curve fits.

$$Y = Bottom + \frac{(Top - Bottom)}{1 + \exp\left(\frac{T_m - X}{Slope}\right)}$$

Equation 6

Where:

Y = the relative concentration of proteins in the unfolded state

X = Temperature ($^{\circ}C$)

T_m = The temperature at which half the protein of interest is unfolded

Quantification and statistical analysis

Comparison of T_m , K_d or K_i values was made using a one-way Analysis Of Variance (ANOVA) test and Tukey's post hoc multiple comparison test. Statistical comparison of T_m values obtained with F-propranolol Vs BODIPYTM FL L-Cystine dye was made using an unpaired t test. All statistical analysis was completed in GraphPad Prism 8 and $p < 0.05$ was considered statistically significant.

Acknowledgements

C.R.H. was funded by a Medical Research Council (MRC) IMPACT PhD studentship.

Author contributions

C.R.H performed the experiments.

C.R.H. wrote the manuscript and it was edited by **D.A.S**, **D.R.P**, **S.J.B** and **D.B.V**

D.A.S gave technical advice and generated reagents.

R.U and **D.R.P** gave technical advice.

B.H and **F.M.H.** generated reagents.

C.R.H, **S.J.B** and **D.B.V** conceived the idea.

S.J.B and **D.B.V** supervised the project

Declaration of interests

D.A.S and D.B.V are founding directors of Z7 Biotech Ltd, an early stage drug discovery company. All other authors declare no conflict of interest.

References

- Adão, R., P. F. Cruz, D. C. Vaz, F. Fonseca, J. N. Pedersen, F. Ferreira-da-Silva, R. M. M. Brito, C. H. I. Ramos, D. Otzen, S. Keller and M. Bastos (2020). "DIBMA nanodiscs keep α -synuclein folded." *Biochimica et Biophysica Acta (BBA) - Biomembranes* **1862**(9).
- Bada Juarez, J. F., J. C. Munoz-Garcia, R. Inacio Dos Reis, A. Henry, D. McMillan, M. Kriek, M. Wood, C. Vandenplas, Z. Sands, L. Castro, R. Taylor and A. Watts (2020). "Detergent-free extraction of a functional low-expressing GPCR from a human cell line." *Biochim Biophys Acta Biomembr* **1862**(3): 183152.
- Baker, J. G. (2005). "The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors." *Br J Pharmacol* **144**(3): 317-322.
- Bang, I. and H. J. Choi (2015). "Structural features of beta2 adrenergic receptor: crystal structures and beyond." *Mol Cells* **38**(2): 105-111.
- Barniol-Xicotà, M. and S. H. L. Verhelst (2021). "Lipidomic and in-gel analysis of maleic acid co-polymer nanodiscs reveals differences in composition of solubilized membranes." *Communications Biology* **4**(1): 218.
- Cherezov, V., D. M. Rosenbaum, M. A. Hanson, S. G. Rasmussen, F. S. Thian, T. S. Kobilka, H. J. Choi, P. Kuhn, W. I. Weis, B. K. Kobilka and R. C. Stevens (2007). "High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor." *Science* **318**(5854): 1258-1265.
- Comeo, E., N. D. Kindon, M. Soave, L. A. Stoddart, L. E. Kilpatrick, P. J. Scammells, S. J. Hill and B. Kellam (2020). "Subtype-Selective Fluorescent Ligands as Pharmacological Research Tools for the Human Adenosine A2A Receptor." *J Med Chem* **63**(5): 2656-2672.
- Dawaliby, R., C. Trubbia, C. Delporte, M. Masureel, P. Van Antwerpen, B. K. Kobilka and C. Govaerts (2016). "Allosteric regulation of G protein-coupled receptor activity by phospholipids." *Nat Chem Biol* **12**(1): 35-39.
- Dorr, J. M., M. C. Koorengel, M. Schafer, A. V. Prokofyev, S. Scheidelaar, E. A. van der Crujisen, T. R. Dafforn, M. Baldus and J. A. Killian (2014). "Detergent-free isolation, characterization, and functional reconstitution of a tetrameric K⁺ channel: the power of native nanodiscs." *Proc Natl Acad Sci U S A* **111**(52): 18607-18612.
- Emami-Nemini, A., T. Roux, M. Leblay, E. Bourrier, L. Lamarque, E. Trinquet and M. J. Lohse (2013). "Time-resolved fluorescence ligand binding for G protein-coupled receptors." *Nat Protoc* **8**(7): 1307-1320.

- Gregorio, G. G., M. Masureel, D. Hilger, D. S. Terry, M. Juetter, H. Zhao, Z. Zhou, J. M. Perez-Aguilar, M. Hauge, S. Mathiasen, J. A. Javitch, H. Weinstein, B. K. Kobilka and S. C. Blanchard (2017). "Single-molecule analysis of ligand efficacy in beta2AR-G-protein activation." *Nature* **547**(7661): 68-73.
- Gulamhussein, A. A., D. Meah, D. D. Soja, S. Fenner, Z. Saidani, A. Akram, S. Lallie, A. Mathews, C. Painter, M. K. Liddar, Z. Mohammed, L. K. Chiu, S. S. Sumar, H. Healy, N. Hussain, J. H. Patel, S. C. L. Hall, T. R. Dafforn and A. J. Rothnie (2019). "Examining the stability of membrane proteins within SMALPs." *European Polymer Journal* **112**: 120-125.
- Gulamhussein, A. A., R. Uddin, B. J. Tighe, D. R. Poyner and A. J. Rothnie (2020). "A comparison of SMA (styrene maleic acid) and DIBMA (di-isobutylene maleic acid) for membrane protein purification." *Biochim Biophys Acta Biomembr* **1862**(7): 183281.
- Gulati, S., M. Jamshad, T. J. Knowles, K. A. Morrison, R. Downing, N. Cant, R. Collins, J. B. Koenderink, R. C. Ford, M. Overduin, I. D. Kerr, T. R. Dafforn and A. J. Rothnie (2014). "Detergent-free purification of ABC (ATP-binding-cassette) transporters." *Biochem J* **461**(2): 269-278.
- Hauser, A. S., M. M. Attwood, M. Rask-Andersen, H. B. Schioth and D. E. Gloriam (2017). "Trends in GPCR drug discovery: new agents, targets and indications." *Nat Rev Drug Discov* **16**(12): 829-842.
- Heydenreich, F., T. Miljuš, D. Milić and D. Veprintsev (2020). "High-throughput Site-directed Scanning Mutagenesis Using a Two-fragment PCR Approach." *Bio-Protocol* **10**(1).
- Heydenreich, F. M., T. Miljus, R. Jaussi, R. Benoit, D. Milic and D. B. Veprintsev (2017). "High-throughput mutagenesis using a two-fragment PCR approach." *Sci Rep* **7**(1): 6787.
- Jamshad, M., J. Charlton, Y. P. Lin, S. J. Routledge, Z. Bawa, T. J. Knowles, M. Overduin, N. Dekker, T. R. Dafforn, R. M. Bill, D. R. Poyner and M. Wheatley (2015). "G-protein coupled receptor solubilization and purification for biophysical analysis and functional studies, in the total absence of detergent." *Biosci Rep* **35**(2).
- Knowles, T. J., R. Finka, C. Smith, Y. P. Lin, T. R. Dafforn and M. Overduin (2009). "Membrane proteins solubilized intact in lipid containing nanoparticles bounded by styrene maleic acid copolymer." *J Am Chem Soc* **131**(22): 7458-7485.
- Leitz, A. J., T. H. Bayburt, A. N. Barnakov, B. A. Springer and S. G. Sligar (2006). "Functional reconstitution of Beta2-adrenergic receptors utilizing self-assembling Nanodisc technology." *Biotechniques* **40**(5): 601-602, 604, 606, passim.
- Manglik, A., T. H. Kim, M. Masureel, C. Altenbach, Z. Yang, D. Hilger, M. T. Lerch, T. S. Kobilka, F. S. Thian, W. L. Hubbell, R. S. Prosser and B. K. Kobilka (2015). "Structural Insights into the Dynamic Process of beta2-Adrenergic Receptor Signaling." *Cell* **161**(5): 1101-1111.
- Mosslehy, W., N. Voskoboynikova, A. Colbasevici, A. Ricke, D. Klose, J. P. Klare, A. Y. Mulkidjanian and H. J. Steinhoff (2019). "Conformational Dynamics of Sensory Rhodopsin II in Nanolipoprotein and Styrene-Maleic Acid Lipid Particles." *Photochem Photobiol* **95**(5): 1195-1204.
- Munk, C., E. Mutt, V. Isberg, L. F. Nikolajsen, J. M. Bibbe, T. Flock, M. A. Hanson, R. C. Stevens, X. Deupi and D. E. Gloriam (2019). "An online resource for GPCR structure determination and analysis." *Nat Methods* **16**(2): 151-162.
- Oluwole, A. O., B. Danielczak, A. Meister, J. O. Babalola, C. Vargas and S. Keller (2017). "Solubilization of Membrane Proteins into Functional Lipid-Bilayer Nanodiscs Using a Diisobutylene/Maleic Acid Copolymer." *Angew Chem Int Ed Engl* **56**(7): 1919-1924.
- Paila, Y. D., E. Jindal, S. K. Goswami and A. Chattopadhyay (2011). "Cholesterol depletion enhances adrenergic signaling in cardiac myocytes." *Biochim Biophys Acta* **1808**(1): 461-465.
- Rasmussen, S. G., B. T. DeVree, Y. Zou, A. C. Kruse, K. Y. Chung, T. S. Kobilka, F. S. Thian, P. S. Chae, E. Pardon, D. Calinski, J. M. Mathiesen, S. T. Shah, J. A. Lyons, M. Caffrey, S. H. Gellman, J. Steyaert, G. Skiniotis, W. I. Weis, R. K. Sunahara and B. K. Kobilka (2011). "Crystal structure of the beta2 adrenergic receptor-Gs protein complex." *Nature* **477**(7366): 549-555.

- Routledge, S. J., M. Jamshad, H. A. Little, Y. P. Lin, J. Simms, A. Thakker, C. M. Spickett, R. M. Bill, T. R. Dafforn, D. R. Poyner and M. Wheatley (2020). "Ligand-induced conformational changes in a SMALP-encapsulated GPCR." Biochim Biophys Acta Biomembr **1862**(6): 183235.
- Schioth, H. B. and R. Fredriksson (2005). "The GRAFS classification system of G-protein coupled receptors in comparative perspective." Gen Comp Endocrinol **142**(1-2): 94-101.
- Stroud, Z., S. C. L. Hall and T. R. Dafforn (2018). "Purification of membrane proteins free from conventional detergents: SMA, new polymers, new opportunities and new insights." Methods **147**: 106-117.
- Sun, C., S. Benlekbir, P. Venkatakrisnan, Y. Wang, S. Hong, J. Hosler, E. Tajkhorshid, J. L. Rubinstein and R. B. Gennis (2018). "Structure of the alternative complex III in a supercomplex with cytochrome oxidase." Nature **557**(7703): 123-126.
- Sykes, D. A., C. Parry, J. Reilly, P. Wright, R. A. Fairhurst and S. J. Charlton (2014). "Establishing "Micro PK/PD" at the β 2-Adrenoceptor." Molecular Pharmacology **85**(4): 608-617.
- Tippett, N. D., B. Hoare, T. Miljus, D. A. Sykes and D. B. Veprintsev (2020). "ThermoFRET: A novel nanoscale G protein coupled receptor thermostability assay functional in crude solubilised membrane preparations." bioRxiv 2020.07.07.191957; doi: <https://doi.org/10.1101/2020.07.07.191957>.
- Wacker, D., G. Fenalti, M. A. Brown, V. Katritch, R. Abagyan, V. Cherezov and R. C. Stevens (2010). "Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography." J Am Chem Soc **132**(33): 11443-11445.
- Whorton, M. R., M. P. Bokoch, S. G. Rasmussen, B. Huang, R. N. Zare, B. Kobilka and R. K. Sunahara (2007). "A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein." Proc Natl Acad Sci U S A **104**(18): 7682-7687.
- Zocher, M., C. Zhang, S. G. Rasmussen, B. K. Kobilka and D. J. Muller (2012). "Cholesterol increases kinetic, energetic, and mechanical stability of the human beta2-adrenergic receptor." Proc Natl Acad Sci U S A **109**(50): E3463-3472.

Tables

Table 1: Ligand binding parameters to different preparations of β_2 AR.

	Membranes			DDM			DIBMA		
	pIC ₅₀	pK _i	Slope	pIC ₅₀	pK _i	Slope	pIC ₅₀	pK _i	Slope
Propranolol	8.7 ±0.13	9.5 ±0.03	1.0 ±0.02	9.0 ±0.04	9.5 ±0.03	1.2 ±0.04	9.1 ±0.10	9.6 ±0.10	0.8 ±0.30
ICI 118,551	8.5 ±0.10	9.3 ±0.15	1.1 ±0.22	8.5 ±0.02	8.9 ±0.10	1.0 ±0.06	8.3 ±0.15	9.1 ±0.06	1.3 ±0.23
Isoprenaline	4.7 ±0.12	5.5 ±0.20	1.1 ±0.11	5.8 ±0.06	6.3 ±0.13	1.1 ±0.09	5.1 ±0.18	5.8 ±0.10	1.1 ±0.15

Note: values shown are mean of n=3 individually fitted curves ±SEM, as determined by TR-FRET competition binding assays.

Table 2. Thermal stability of different preparations of β_2 AR.

	T _m (°C) ThermoFRET	T _m (°C) F-ligand
Membrane β_2 AR	62.4±0.2	-
Membrane β_2 AR + F-propranolol	61.6±0.4	60.1±0.6 ^a
Membrane β_2 AR + cyanopindolol	63.0±0.4	-
DDM β_2 AR	35.2±2.4	-
DDM β_2 AR + F-propranolol	37.8 ±0.4	36.0 ±0.6 ^a
DDM β_2 AR + cyanopindolol	41.9 ±0.1	-
DIBMALP β_2 AR	-	46.8 ±2.1 ^a
DIBMALP A _{2A} + F-XAC	-	44.8 ±0.7 ^b

Note: reported error values are **SEM**

^a β_2 AR thermostability was measured using F-propranolol dissociation

^bDIBMALP-A_{2A} thermostability was measured using F-XAC dissociation




Figure titles and legends







Figure 1: Solubilisation of β_2 AR from the mammalian cell membrane using DDM and DIBMA. **A)** Representative in gel fluorescence (cy5) of purified DDM- β_2 AR and DIBMALP- β_2 AR **B)** Solubilisation of DDM Vs DIBMA, Alexa488 labelled β_2 AR was quantified and percentage of membrane calculated ($n=3 \pm$ SEM). **C)** FSEC analysis of DDM- β_2 AR and DIBMA- β_2 AR samples using Yarra X300 column (Mean of $n=3$).




Figure 2: A comparison of F-propranolol binding to β_2 AR in membranes, DDM and DIBMALPs. **A-C)** Representative F-propranolol (2-666nM) equilibrium saturation plots showing total and non-specific binding to the β_2 AR in (A) HEK cell membranes, (B) DDM and (C) DIBMALPs, $n=1$. **D-F)** Saturation binding curves showing specific binding and associated affinity (pK_d) values for F-propranolol binding to the β_2 AR in (D) HEK cell membranes, (E) DDM and (F) DIBMALPs, curves show combined normalised data mean \pm SEM, $n=3$.





Figure 3: Competition TR-FRET ligand binding studies using F-propranolol as a tracer and unlabelled propranolol, ICI 118,551 and isoprenaline as competitors. **A)** β_2 AR membranes, **B)** DDM- β_2 AR **C)** DIBMALP- β_2 AR, curves show normalized combined data of $n=3$, error bars show \pm SEM.

Figure 4: ThermoFRET thermostability curves in **A)** β_2 AR membranes **B)** DDM solubilised β_2 AR **C)** DIBMALP- β_2 AR in the presence and absence of cyanopindolol (100 μ M) and F-propranolol (200nM). **D)** β_2 AR and A_2 AR TR-FRET thermostability curves obtained by measuring reduction in fluorescent F-propranolol (200nM) and F-XAC (200nM) binding. All curves show normalized combined data, data points show mean \pm SEM, for $n=3$.



A**B****C****D****E****F**

A**B****C**



Please upload a single Word document that includes up to four Highlights. Each highlight can be no more than 89 characters, including spaces

- DIBMA can be used to extract the human β_2 AR from mammalian cells
- DIBMALP- β_2 AR retains ligand binding ability and shows improved stability
- Our novel TR-FRET based ligand binding methods removed the need for purification for DIBMALP- β_2 AR characterisation

Journal Pre-proof